Facts Matter (Feb. 9): Pfizer Quietly Adds Warning That ‘Unfavorable Pre-Clinical, Clinical, or Safety Data’ May Impact Business

As we get closer and closer to the day that the FDA has to release its first batch of 55,000 pages of clinical trial documents, it looks like Pfizer is bracing for impact. That’s because it was just revealed that Pfizer updated its fourth-quarter investor report—the section on potential risks to their business. Specifically, t...